Effect of azithromycin, as an adjunct to nonsurgical periodontal treatment, on microbiological parameters and gingival crevicular fluid biomarkers in generalized aggressive periodontitis

Journal of Periodontal Research

Volumn 47, Issue 6, 2012, Pages 729-739

  Emingil, G ^a   Han, B ^a   Ozdemir G ^a   Tervahartiala, T ^b   Vural, C ^a   Atilla, G ^a   Baylas, H ^a   Sorsa, T ^b,c  

^a EGE UNIVERSITY   (Turkey)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adjunctive therapy; Azithromycin scaling and root planing; Generalized aggressive periodontitis; Gingival crevicular fluid MMP 8; Tissue inhibitor of matrix metalloproteinase 1

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL DNA; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ADULT; AGGRESSIVE PERIODONTITIS; ANAEROBIC BACTERIUM; ARTICLE; CHEMISTRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENETICS; GINGIVITIS; HUMAN; MALE; METABOLISM; MICROBIOLOGY; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL; TOOTH PLAQUE;

ADOLESCENT; ADULT; AGGRESSIVE PERIODONTITIS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIA, ANAEROBIC; DENTAL PLAQUE; DENTAL SCALING; DNA, BACTERIAL; DOUBLE-BLIND METHOD; FEMALE; GINGIVAL CREVICULAR FLUID; HUMANS; MALE; MATRIX METALLOPROTEINASE 8; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 84867232119     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2012.01488.x     Document Type: Article

References (58)

1. Tonetti MS, Mombelli A. Early-onset periodontitis. Ann Periodontol 1999;4:39-53.
2. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-7.
3. Meng H, Xu L, Li Q, Han J, Zhao Y. Determinants of host susceptibility in aggressive periodontitis. Periodontol 2000 2007;43:133-159.
4. Albandar JM, Brown LJ, Löe H. Putative periodontal pathogens in subgingival plaque of young adults with and without early-onset periodontitis. J Periodontol 1997;68:973-981.
5. Takahashi K, Ohyama H, Kitanaka M et al. Heterogeneity of host immunological risk factors in patients with aggressive periodontitis. J Periodontol 2001;72:425-437.
6. Emingil G, Atilla G, Başkesen A, Berdeli A. Gingival crevicular fluid EMAP-II, MIP-1alpha and MIP-1beta levels of patients with periodontal disease. J Clin Periodontol 2005;32:880-885.
7. Moore WE, Moore LV. The bacteria of periodontal diseases. Periodontol 2000 1994;5:66-77.
8. Mullally BH, Dace B, Shelburne CE, Wolff LF, Coulter WA. Prevalence of periodontal pathogens in localized and generalized forms of early-onset periodontitis. J Periodont Res 2000;35:232-241.
9. Faveri M, Mayer MP, Feres M, de Figueiredo LC, Dewhirst FE, Paster BJ. Microbiological diversity of generalized aggressive periodontitis by 16S rRNA clonal analysis. Oral Microbiol Immunol 2008;23:112-118.
10. Deas DE, Mealey BL. Response of chronic and aggressive periodontitis to treatment. Periodontol 2000 2010;53:154-166.
11. Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-infective periodontal therapy. A systematic review. Ann Periodontol 2003;8:115-181.
12. Herrera D, Alonso B, León R, Roldán S, Sanz M. Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm. J Clin Periodontol 2008;35(Suppl.8):45-66.
13. Foulds G, Shepard RM, Johnson RB. The pharmokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25:73-82.
14. Culić O, Eraković V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharm Sci 2001;429:209-229.
15. Retsema J, Girard A, Schelkly W et al. Spectrum and mode of action of azithyromycin (CP-62, 993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987;31:1939-1947.
16. Malizia T, Tejada MR, Ghelardi E et al. Periodontal tissue disposition of azithromycin. J Periodontol 1997;68:1206-1209.
17. Blandizzi C, Malizia T, Lupetti A. Periodontal tissue disposition of azithyromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol 1999;70:960-966.
18. Gomi K, Yashima A, Iino F et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol 2007;78:918-923.
19. Hirsch R, Deng H, Laohachai MN. Azithromycin in periodontal treatment: more than an antibiotic. J Periodontal Res 2012;47:137-148.
20. Ianaro A, Ialenti A, Maffia P et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-163.
21. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008;31:12-20.
22. Dastoor SF, Travan S, Neiva RF, Rayburn LA, Giannobile WV, Wang HL. Effect of adjunctive systemic azithromycin with periodontal surgery in the treatment of chronic periodontitis in smokers: a pilot study. J Periodontol 2007;78:1887-1896.
23. Haffajee AD, Torresyap G, Socransky SS. Clinical changes following four different periodontal therapies for the treatment of chronic periodontitis: 1-year results. J Clin Periodontol 2007;34:243-253.
24. Yashima A, Gomi K, Maeda N, Arai T. One-stage full-mouth versus partial-mouth scaling and root planning during the effective half-life of systemically administered azithromycin. J Periodontol 2009;80:1406-1413.
25. Oteo A, Herrera D, Figuero E, O'Connor A, González I, Sanz M. Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis-associated periodontitis: a pilot study. J Clin Periodontol 2010;37:1005-1015.
26. Sampaio E, Rocha M, Figueiredo LC et al. Clinical and microbiological effects of azithromycin in the treatment of generalized chronic periodontitis: a randomized placebo-controlled clinical trial. J Clin Periodontol 2011;38:838-846.
27. Smith SR, Foyle DM, Daniels J et al. A double-blind placebo-controlled trial of azithromycin as an adjunct to non-surgical periodontal treatment of periodontitis in adults: clinical results. J Clin Periodontol 2002;29:54-61.
28. Haas AN, de Castro GD, Moreno T et al. Azithromycin as an adjunctive treatment of aggressive periodontitis: 12-months randomized clinical trial. J Clin Periodontol 2008;35:696-704.
29. Lamster IB, Hartley LJ, Vogel RI. Development of a biochemical profile for gingival crevicular fluid. Methodological considerations and evaluation of collagen-degrading and ground substance-degrading enzyme activity during experimental gingivitis. J Periodontol 1985;56:13-21.
30. Cimasoni G. (1983). Method of collection. In: Howard MM, ed. Crevicular fluid updated. Monographs in Oral Science. Vol.12, 2nd edition. Basel: Karger, 1983:29-36.
31. Hanemaaijer R, Sorsa T, Konttinen YT et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-α and doxycycline. J Biol Chem 1997;272:31504-31509.
32. Becerik S, Türkoǧlu O, Emingil G, Vural C, Özdemir G, Atilla G. Anti-microbial effect of adjunctive use of chlorhexidine mouthrinse in untreated gingivitis: a randomized, placebo-controlled study. APMIS 2011;114:364-372.
33. Cobb CM. Non-surgical pocket therapy: mechanical. Ann Periodontol 1996;1:443-490.
34. Greenstein G. Periodontal response to mechanical non-surgical therapy: a review. J Periodontol 1992;63:118-130.
35. Wennström A, Wennström J, Lindhe J. Healing following surgical and non-surgical treatment of juvenile periodontitis. A 5-year longitudinal study. J Clin Periodontol 1986;13:869-882.
36. Darby IB, Hodge PJ, Riggio MP, Kinane DF. Clinical and microbiological effect of scaling and root planning in smoker and non-smoker chronic and aggressive periodontitis patients. J Clin Periodontol 2005;32:200-206.
37. Hughes FJ, Syed M, Koshy B et al. Prognostic factors in the treatment of generalized aggressive periodontitis: I. Clinical features and initial outcome. J Clin Periodontol 2006;33:663-670.
38. Chen HY, Cox SW, Eley BM, Mantyla P, Ronka H, Sorsa T. Matrix metalloproteinase-8 levels and elastase activities in gingival crevicular fluid from chronic adult periodontitis patients. J Clin Periodontol 2000;27:366-369.
39. Mäntylä P, Stenman M, Kinane DF et al. Gingival crevicular fluid collagenase-2 (MMP-8) test stick for chair-side monitoring of periodontitis. J Periodont Res 2003;34:436-439.
40. Marcaccini AM, Meschiari CA, Zuardi LR et al. Gingival crevicular fluid levels of MMP-8, MMP-9, TIMP-2, and MPO decrease after periodontal therapy. J Clin Periodontol 2010;37:180-190.
41. Suomalainen K, Sorsa T, Saxén L, Vauhkonen M, Uitto VJ. Collagenase activity in gingival crevicular fluid of patients with juvenile periodontitis. Oral Microbiol Immunol 1991;6:24-29.
42. Tervahartiala T, Pirilä E, Ceponis A et al. The in vivo expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized juvenile periodontitis. J Dent Res 2000;79:1969-1977.
43. Alfant B, Shaddox LM, Tobler J, Magnusson I, Aukhil I, Walker C. Matrix metalloproteinase levels in children with aggressive periodontitis. J Periodontol 2008;79:819-826.
44. Hernández M, Gamonal J, Tervahartiala T et al. Associations between matrix metalloproteinase-8 and -14 and myeloperoxidase in gingival crevicular fluid from subjects with progressive chronic periodontitis: a longitudinal study. J Periodontol 2010;8:1644-1652.
45. Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000 2002;28:12-55.
46. Teles RP, Haffajee AD, Socransky SS. Microbiological goals of periodontal therapy. Periodontol 2000 2006;42:180-218.
47. Haffajee AD, Teles RP, Socransky SS. The effect of periodontal therapy on the composition of the subgingival microbiota. Periodontol 2000 2006;42:219-258.
48. Umeda M, Takeuchi Y, Noguchi K, Huang Y, Koshy G, Ishikawa I. Effects of nonsurgical periodontal therapy on the microbiota. Periodontol 2000 2004;36:98-120.
49. Pajukanta R. In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol 1993;8:325-326.
50. Jain N, Lai PC, Walters JD. Effect of Gingivitis on Azithromycin Concentrations in Gingival Crevicular Fluid. J Periodontol 2012; doi: 10.1902/jop.2012.110558. [Epub ahead of print].
51. Sefton AM, Maskell JP, Beighton D et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J ClinPeriodontol 1996;23:998-1003.
52. Gomi K, Yashima A, Nagano T, Kanazashi M, Maeda N. Effects of full-mouth scaling and root planning in conjunction with systemically administered azithromycin. J Periodontol 2007;78:422-429.
53. Loesche WJ, Giordano JR. Metronidazole in periodontitis V: debridement should precede medication. Compendium 1994;15:1198, 1201.
54. Socransky SS, Haffajee AD. The bacterial etiology of destructive periodontal disease: current concepts. J Periodontol 1992;63:322-331.
55. Sanz M, Teughels W; Group A of European Workshop on Periodontology. Innovations in non-surgical periodontal therapy: Consensus Report of the Sixth European Workshop on Periodontology. J Clin Periodontol 2008;35(Suppl. 8):3-7.
56. Guerrero A, Griffiths GS, Nibali L et al. Adjunctive benefits of systemic amoxicillin and metronidazole in non-surgical treatment of generalized aggressive periodontitis: a randomized placebo-controlled clinical trial. J Clin Periodontol 2005;32:1096-1107.
57. Kaner D, Christan C, Dietrich T, Bernimoulin JP, Kleber BM, Friedmann A. Timing affects the clinical outcome of adjunctive systemic antibiotic therapy for generalized aggressive periodontitis. J Periodontol 2007;78:1201-1208.
58. Griffiths GS, Ayob R, Guerrero A et al. Amoxicillin and metronidazole as an adjunctive treatment in generalized aggressive periodontitis at initial therapy or re-treatment: a randomized controlled clinical trial. J Clin Periodontol 2011;38:43-49.